A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3),a human anti-PDGFRα
MoAb, with or without doxorubicin, in advanced STS
William D. Tap, Robin L Jones, Bartosz Chmielowski, Anthony D. Elias, Douglas Adkins, Brian Andrew Van Tine, Mark
Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory K. Pennock, Amy Qin, Ashwin Shahir, Robert L. Ilaria, Ilaria
Conti, Jan Cosaert, Gary K. Schwartz;
